This randomized, placebo-controlled study evaluates the effects of CuraMed ® (BCM-95 ®) and Curamin ® in the treatment of osteoarthritis. One group will receive CuraMed, one group will receive Curamin and one group will receive placebo.

Inclusion Criteria:

• Patients with a diagnosis of degenerative hypertrophic osteoarthritis of the knee (M17, according to International Classification of Diseases (ICD-10) of bone joints, verified by radiography (Grade 1-3 by Kellgren-Lawrence radiographic grades).

Exclusion Criteria:

• subjects with inflammatory and any secondary arthritis
• moderate and severe synovitis (grades 2 and 3)
• tear of meniscus
• chronic diseases of the kidneys, liver, gastrointestinal, cardiovascular, endocrine and nervous systems
• allergic anamnesis and drug intolerance
• pregnant or nursing
• history of substance abuse
• subjects taking non-steroidal anti-inflammatory drugs and analgesics within 2 weeks prior to the study
• subjects taking glucosamine sulfate, chondroitin sulfate, intra-articular hyaluronate, systemic or intra-articular glucocorticoids within three months prior to the study